EdgeWater Research Partners, LLC (www.edgewaterresearch.com), an independent micro cap equities research company, has initiated coverage on GeoPharma, Inc. with an 18- to 24-month target price of $7.25 and an allocation rating of four or Buy. EdgeWater tracks a variety of undiscovered small and micro cap stocks through both individual research and its monthly publication, The EdgeWater Micro Monthly.

With nearly 300 employees and operations in Florida, Maryland, Pennsylvania, Nevada, Rhode Island and Texas, GeoPharma, Inc. is a biotech/pharmaceutical company that specializes in the formulation, manufacturing and distribution of generic drugs and the development of oncology-related medical devices.

The company distributes of a variety of over-the-counter formulations, including nutraceuticals, vitamins, skin care products and others to some the nation’s largest retailers, such as Wal-Mart, Walgreens, CVS/pharmacy, GNC and several others. GeoPharma also private labels their products through contract manufacturing arrangements. In addition, GeoPharma is just now beginning to market its first products into the generic pharmaceutical space, which could provide a considerable growth catalyst for the company going forward.

Let us hear your thoughts: